Clinical and laboratory observationManagement of neonatal Graves disease with iopanoic acid**
References (10)
The thyroid
- et al.
Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate
J Clin Endocrinol Metab
(1987) Thyroid diseases in pregnancy
- et al.
Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography
J Clin Endocrinol Metab
(1978) - et al.
The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism
J Clin Endocrinol Metab
(1978)
There are more references available in the full text version of this article.
Cited by (22)
Review of oral cholecystographic agents for the management of hyperthyroidism
2014, Endocrine PracticeCitation Excerpt :One series compared OCAs with a thionamide and potassium iodide, which showed similar outcomes (39). OCAs have been noted to be safe and effective in neonatal Graves’ disease (21-24) and thyrotoxicosis due to TSH-oma (52). In toxic multinodular goiter, there was a relatively high rate of relapse after OCA treatment (48), likely due to autonomously functioning thyroid nodules that use excess available iodine released by OCAs.
Thyrotoxicosis in children
1998, Endocrinology and Metabolism Clinics of North AmericaNeonatal thyrotoxicosis
1997, Current PaediatricsTreatment of neonatal hyperthyroidism with calcium ipodate
1996, Archives de PediatrieThyroid disorders in infancy
2013, Pediatric Endocrinology: Fifth EditionDisorders of thyroid function
2012, Neonatology: A Practical Approach to Neonatal Diseases
- **
In private practice, 29877 Telegraph Rd., Farmbrook Medical Two, Suite 303, Southfield, MI 48034.
- *
Now a fellow in neonatal-perinatal medicine, Milton S. Hershey Medical Center, Hershey, Pa.
Copyright © 1992 Published by Mosby, Inc.